David H. Harpole

19.9k total citations · 3 hit papers
203 papers, 12.8k citations indexed

About

David H. Harpole is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, David H. Harpole has authored 203 papers receiving a total of 12.8k indexed citations (citations by other indexed papers that have themselves been cited), including 157 papers in Pulmonary and Respiratory Medicine, 60 papers in Oncology and 52 papers in Surgery. Recurrent topics in David H. Harpole's work include Lung Cancer Diagnosis and Treatment (101 papers), Lung Cancer Treatments and Mutations (75 papers) and Esophageal Cancer Research and Treatment (31 papers). David H. Harpole is often cited by papers focused on Lung Cancer Diagnosis and Treatment (101 papers), Lung Cancer Treatments and Mutations (75 papers) and Esophageal Cancer Research and Treatment (31 papers). David H. Harpole collaborates with scholars based in United States, United Kingdom and Japan. David H. Harpole's co-authors include Thomas A. D’Amico, James E. Herndon, Mark W. Onaitis, William R. Burfeind, Mark F. Berry, Betty C. Tong, Eric M. Toloza, Walter G. Wolfe, Rebecca P. Petersen and David J. Sugarbaker and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

David H. Harpole

200 papers receiving 12.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non–Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups

2008 690 citations Gary M. Strauss, James E. Herndon et al. Journal of Clinical Oncology profile →
Thoracoscopic lobectomy is associated with lower morbidity than open lobectomy: A propensity-matched analysis from the STS database

2010 586 citations Nasser K. Altorki, David H. Harpole et al. Journal of Thoracic and Cardiovascular Surgery profile →
Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies

2017 266 citations Paul J. Speicher, David H. Harpole et al. profile →

Peers

Countries citing papers authored by David H. Harpole

Since Specialization

Citations

This map shows the geographic impact of David H. Harpole's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David H. Harpole with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David H. Harpole more than expected).

Fields of papers citing papers by David H. Harpole

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David H. Harpole. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David H. Harpole. The network helps show where David H. Harpole may publish in the future.

Co-authorship network of co-authors of David H. Harpole

This figure shows the co-authorship network connecting the top 25 collaborators of David H. Harpole. A scholar is included among the top collaborators of David H. Harpole based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David H. Harpole. David H. Harpole is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Abstract CT005: AEGEAN: A phase 3 trial of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC 2023 ·Cancer Research ·John V. Heymach, David H. Harpole, Tetsuya Mitsudomi, Janis M. Taube, Gabriella Gálffy, Maximilian J. Hochmair, Thomas Winder, Р. А. Зуков, Gabriel Garbaos, Shugeng Gao, Hiroaki Kuroda, Jian You, Kang‐Yun Lee, Lorenzo Antonuzzo, Mike Aperghis, Gary J. Doherty, Helen Mann, Tamer M. Fouad, Martin Reck	55
2	The Society of Thoracic Surgeons/American Society for Radiation Oncology Updated Clinical Practice Guidelines on Multimodality Therapy for Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction 2023 ·The Annals of Thoracic Surgery ·Stephanie G. Worrell, Karyn A. Goodman, Nasser K. Altorki, Jonathan B. Ashman, Traves D. Crabtree, Jennifer A. Dorth, Scott Firestone, David H. Harpole, Wayne L. Hofstetter, Theodore S. Hong, Kalie Kissoon, Geoffrey Y. Ku, Daniela Molena, Joel E. Tepper, Thomas J. Watson, Terence M. Williams, Christopher G. Willett	5
3	Stellate Ganglion Blockade for the Treatment of Refractory Ventricular Arrhythmias 2020 ·JACC. Clinical electrophysiology ·Marat Fudim, Yawar J. Qadri, Nathan H. Waldron, Richard L. Boortz-Marx, Arun Ganesh, Chetan B. Patel, Mihai V. Podgoreanu, Albert Y. Sun, Carmelo A. Milano, Betty C. Tong, David H. Harpole, Joseph P. Mathew, Jonathan P. Piccini	53
4	The effect of extent of resection on outcomes in patients with limited stage small cell lung cancer 2020 ·Journal of Thoracic and Cardiovascular Surgery ·Vignesh Raman, Oliver K. Jawitz, Chi‐Fu Jeffrey Yang, Soraya L. Voigt, Thomas A. D’Amico, David H. Harpole, Betty C. Tong	7
5	Stellate Ganglion Blockade: an Intervention for the Management of Ventricular Arrhythmias 2020 ·Current Hypertension Reports ·Arun Ganesh, Yawar J. Qadri, Richard L. Boortz-Marx, Sana M. Al‐Khatib, David H. Harpole, Jason N. Katz, Jason I. Koontz, Joseph P. Mathew, (unknown), Albert Y. Sun, Betty C. Tong, Luis Ulloa, Jonathan P. Piccini, Marat Fudim	39
6	The influence of adjuvant therapy on survival in patients with indeterminate margins following surgery for non–small cell lung cancer 2019 ·Journal of Thoracic and Cardiovascular Surgery ·Vignesh Raman, Oliver K. Jawitz, Chi‐Fu Jeffrey Yang, Soraya L. Voigt, Anthony W. Kim, Betty C. Tong, Thomas A. D’Amico, David H. Harpole	3
7	The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation 2019 ·Journal of Thoracic Oncology ·Daniel R. Gomez, Andreas Rimner, Charles B. Simone, John Cho, Marc de Perrot, Alex A. Adjei, Raphael Bueno, Ritu R. Gill, David H. Harpole, Mary Hesdorffer, Fred R. Hirsch, (unknown), Harvey I. Pass, David C. Rice, Valerie W. Rusch, Anne S. Tsao, Ellen Yorke, Kenneth E. Rosenzweig	49
8	Outcomes of surgery versus chemoradiotherapy in patients with clinical or pathologic stage N3 non–small cell lung cancer 2019 ·Journal of Thoracic and Cardiovascular Surgery ·Vignesh Raman, Oliver K. Jawitz, Chi‐Fu Jeffrey Yang, Soraya L. Voigt, Hanghang Wang, Thomas A. D’Amico, David H. Harpole, Betty C. Tong	9
9	Prevalence and resource utilization for vocal fold paralysis/paresis after esophagectomy 2018 ·The Laryngoscope ·Matthew G. Crowson, Betty C. Tong, Hui‐Jie Lee, (unknown), David H. Harpole, Harrison N. Jones, Seth M. Cohen	4
10	Immune Activation in Early-Stage Non–Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab 2017 ·Clinical Cancer Research ·John S. Yi, Neal Ready, Patrick Healy, (unknown), (unknown), Mark F. Berry, (unknown), Jeffrey Clarke, Jeffrey Crawford, Betty C. Tong, David H. Harpole, Thomas A. D’Amico, Frances McSherry, Frank Dunphy, Shannon J. McCall, Jared D. Christensen, Xiaofei Wang, Kent J. Weinhold	62
11	Surgery Versus Optimal Medical Management for N1 Small Cell Lung Cancer 2017 ·The Annals of Thoracic Surgery ·Chi‐Fu Jeffrey Yang, Derek Y. Chan, Paul J. Speicher, Brian C. Gulack, Betty C. Tong, Matthew G. Hartwig, Chris R. Kelsey, Thomas A. D’Amico, Mark F. Berry, David H. Harpole	25
12	Sleeve Lobectomy for Non-Small Cell Lung Cancer With N1 Nodal Disease Does Not Compromise Survival 2013 ·The Annals of Thoracic Surgery ·Mark F. Berry, Mathias Worni, Xiaofei Wang, David H. Harpole, Thomas A. D’Amico, Mark W. Onaitis	19
13	Molecular Analysis-Based Treatment Strategies for the Management of Non-small Cell Lung Cancer 2009 ·Journal of Thoracic Oncology ·Howard West, Rogério Lilenbaum, David H. Harpole, Antoinette J. Wozniak, Lecia V. Sequist	30
14	Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non–Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups breakdown → 2008 ·Journal of Clinical Oncology ·Gary M. Strauss, James E. Herndon, Michael A. Maddaus, David W. Johnstone, Elizabeth A. Johnson, David H. Harpole, Heidi H. Gillenwater, Dorothy Watson, David J. Sugarbaker, Richard L. Schilsky, Everett E. Vokes, Mark R. Green	690
15	Thoracoscopic Lobectomy Facilitates the Delivery of Chemotherapy after Resection for Lung Cancer 2007 ·The Annals of Thoracic Surgery ·Rebecca P. Petersen, DuyKhanh Pham, William R. Burfeind, Steven I. Hanish, Eric M. Toloza, David H. Harpole, Thomas A. D’Amico	214
16	Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. 2003 ·PubMed ·Michael S. Kinch, (unknown), David H. Harpole	199
17	Effects of Valve Replacement on Ventricular Mechanics in Mitral Regurgitation and Aortic Stenosis 1996 ·The Annals of Thoracic Surgery ·David H. Harpole, Stanley A. Gall, Walter G. Wolfe, J S Rankin, Robert H. Jones	23
18	A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. 1995 ·PubMed ·David H. Harpole, (unknown), Walter G. Wolfe, J. Dirk Iglehart, (unknown)	252
19	Localized adenocarcinoma of the lung: Oncogene expression of erbB-2 and p53 in 150 patients 1995 ·Lung Cancer ·David H. Harpole, Jeffrey R. Marks, William G. Richards, James E. Herndon, David J. Sugarbaker	62
20	Early and late changes in left ventricular systolic performance after percutaneous aortic balloon valvuloplasty 1990 ·The American Journal of Cardiology ·David H. Harpole, Charles J. Davidson, Thomas N. Skelton, Katherine B. Kisslo, Robert H. Jones, (unknown)	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact